Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Decline: Should Investors Consider Selling?

On January 2nd, 2025, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock price drop by 7.8%. The stock traded as low as $0.33 and closed at the same price for the day. A considerable volume of 39,393,920 shares was traded, marking an increase of 28% compared to the average daily volume of 30,856,506 shares. The previous closing price was $0.36.

Recent Analyst Ratings

In other developments, StockNews.com initiated coverage on Tonix Pharmaceuticals, offering a "hold" rating in their latest research report.

Performance Overview of Tonix Pharmaceuticals

Tonix Pharmaceuticals demonstrates solid financial metrics, boasting a quick ratio of 2.81 and a current ratio of 3.33. Moreover, its debt-to-equity ratio stands at a low 0.07. The company has a market capitalization of approximately $61.64 million, yet it reports a negative PE ratio of -0.01 and a high beta of 2.23. Over the past 50 days, the stock has averaged $0.23, while its 200-day average price is $0.37.

The latest quarterly earnings report released on November 12th, 2023, revealed an EPS of -$0.23, surpassing analyst expectations which estimated -$2.03 by a remarkable $1.80. The company reported revenues of $2.82 million, which exceeded the anticipated $2.63 million. However, Tonix Pharmaceuticals continues to face challenges, evidenced by a staggering negative net margin of 1,197.86% and a negative return on equity of 163.95%. Analysts forecast that the company will record an EPS of -$17.63 for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a biopharmaceutical firm dedicated to the development, discovery, commercialization, and licensing of therapies aimed at treating and preventing human diseases. Notably, it markets Zembrace SymTouch and Tosymra, which are designed for treating acute migraines in adults.

Additional Resources

Stay updated with the latest news and ratings for Tonix Pharmaceuticals. Enter your email below to receive concise daily summaries and insights.

Tonix, Pharmaceuticals, Stock